NanoLuc technology developed using a split NanoLuc biosensor, enables simple mix-and-read detection of Nipah virus antibodies. The biosensor is 98.6 sensitive and 100% specific for detecting IgG antibodies in Nipah virus infected patients. The NanoLuc Biosensor thus offers a fast, sensitive, and scalable approach for serological surveillance and retrospective analysis of the deadliest viral infections
Scientist have identified the VV116 as a drug to control growth of Nipah virus and prevent development of acute encephalitis. At an effective dose of 400mg/kg in humans, the virus demonstrated favourable pharmacokinetics, minimal tissue damage and improved survival rates of 67%, VV116 is suggested as an effective oral therapeutic candidate against Nipah virus.
Drug VV116 New Hope in the Fight Against Nipah Virus Read More »
Scientists have discovered strains of Ideonella sakaiensis that can degrade polyethylene terephthalate (PET), a plastic commonly used in beverage bottles, packaging containers, and synthetic fibres. These bacteria utilize the enzymes PETase and MHETase to degrade PET as its major energy and carbon source, achieving 100-fold efficiency at room temperatures within approximately 6 weeks.
A Bacteria That Destroy Plastics A Sustainable Solution to PET Pollution Read More »
A breath analyzer based on a hierarchical deep convolutional neural network (HD-CNN) framework can detect and classify cancer subtypes with accuracies of 95.1% and 98.1% for lung and gastric cancers, respectively. The sensor array within the device detects volatile organic compounds present in the breath of cancer patients and converts these signals into digital data for analysis.
Your Breath Could Reveal Cancer: How AI Is Changing Early Detection Read More »
Preclinical screening strategy for T-cell therapies, developed by Sanderson and colleagues at the (Adaptimmune (ADAPY), provides a comprehensive framework to evaluate the safety and efficacy of T-cell therapies like CAR-T and SPEAR- T therapies, helping to minimize the unexpected toxicities before advancing engineered T cells into human trials.
Tecelra, an affinity-enhanced MAGE-A4–specific TCR approved for its efficacy against metastatic synovial sarcoma with minimal off-target risk. The gene therapy showed strong antigen-specific cytokine release, effective tumor cell killing in 2D and 3D models, and dose-dependent tumor regression with complete survival in vivo with manageable alloreactivity and limited cross-reactivity.
Tecelra and MAGE-A4: A Safer, High-Affinity Adoptive T-Cell Immunotherapy Read More »
